Debiovision inc, formerly H3 Pharma, a speciality pharmaceutical developer joins the Debio companies
Debiovision complements the existing synergistic companies in the Debio Group: Debiopharm, Debioinnovation and Debio R.P. in Switzerland and Debioclinic in France.
Founded in 2001, Debiovision will build on Debio's proven drug development business model, with a focus on the development and world-wide registration of specialty pharmaceuticals. In addition, Debiovision will provide support to and work in synergy with the Group on development and regulatory activities in North America. In particular, Debiovision will enable the Group to optimise its Phase I clinical trial activities in Canada. Debiovision has three products in its pipeline including Sanvar(TM), which was submitted to the US Food and Drug Administration (FDA) and received an approvable letter in December 2004, and SC-1 and PAM-1, two fully human monoclonal antibodies.
Debiovision is actively negotiating out-licensing agreements for Sanvar(TM) with US, Asian and Latin American partners and is beginning out- licensing discussions in Europe in conjunction with the preparation of the European filing. Sanvar(TM) is for the treatment of acute esophageal variceal bleeding (EVB) secondary to portal hypertension. Debio's new Quebec-based affiliate is also undertaking out-licensing activities for two fully human monoclonal antibodies, SC-1 for stomach cancer and PAM-1 for adenocarcinomas, including pancreatic cancer.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous